New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export TVRD’s income statement to Excel — free account
Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
0.99
0.04
+4.21%
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Revenue to profit Fiscal 2024, year to Dec 31, 2024
It lost $29.4M on $7.1M of revenue: $411.90 for every $100. What is an income statement?
| Revenue | 7.1 | 100.0% |
|---|---|---|
| Cost of revenue | −0.6 | −8.7% |
| Gross profit | 6.5 | 91.3% |
| Research & development | −23.7 | −331.4% |
| Selling, general & admin | −4.5 | −62.4% |
| Other operating costs | −6.5 | −91.3% |
| Operating income | −28.1 | −393.8% |
| Other income, net | −1.3 | −18.1% |
| Income tax | +0.4 | 5.6% |
| Other items | −0.4 | −5.6% |
| Net income | −29.4 | −411.9% |
Net margin (right axis)
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.9M | $13M | $20M | $135M | $23M | $42M | $21M | $7.1M |
| Operating income | −$58M | −$59M | −$77M | −$112M | $5.4M | −$89M | −$88M | −$121M | −$28M |
| Net income | −$57M | −$58M | −$74M | −$106M | $8.4M | −$88M | −$85M | −$119M | −$29M |
| Net margin (right axis) | −66604.7% | −6380.4% | −549.5% | −534.9% | 6.2% | −384.1% | −204.2% | −565.2% | −411.9% |
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
0.09 | 0.91 | 13.47 | 19.89 | 135.08 | 23.03 | 41.87 | 20.97 | 7.14 | — |
Revenue Growth |
(97.74%) | 959.30% | 1,378.49% | 47.64% | 579.28% | (82.95%) | 81.81% | (49.92%) | (65.96%) | — |
Cost of Revenue |
— | — | — | — | — | 1.55 | 7.27 | 6.17 | 0.62 | — |
Gross Profit |
0.09 | 0.91 | 13.47 | 19.89 | 135.08 | 23.03 | 34.60 | 14.79 | 6.52 | — |
R&D Expenses |
49.25 | 48.52 | 75.53 | 113.82 | 107.85 | 82.70 | 91.88 | 108.51 | 23.65 | 18.01 |
SG&A Expenses |
9.23 | 11.87 | 15.32 | 17.75 | 21.85 | 29.41 | 30.26 | 27.78 | 4.46 | 8.74 |
Operating Income |
(58.40) | (59.48) | (77.38) | (111.68) | 5.39 | (89.08) | (87.53) | (121.49) | (28.11) | (26.75) |
Non-operating Income/Expense |
0.65 | 1.16 | 2.98 | 4.49 | 2.33 | 0.64 | 2.06 | 2.98 | (1.29) | 8.53 |
| (57.75) | (58.33) | (74.40) | (107.19) | 7.72 | (88.44) | (85.47) | (118.51) | (29.40) | (18.21) | |
Income Tax Provision |
(0.47) | (0.20) | (0.39) | (0.82) | (0.69) | — | — | — | (0.40) | — |
Income after Tax |
(57.28) | (58.12) | (74.01) | (106.37) | 8.41 | (88.44) | (85.47) | (118.51) | (29.40) | (18.21) |
Dividends (Preferred) |
0.00 | — | — | — | — | — | — | — | — | — |
Net Income Common |
(57.28) | (58.12) | (74.01) | (106.37) | 8.41 | (88.44) | (85.47) | (118.51) | (29.40) | (18.21) |
EPS (Basic) |
(75.64) | (66.99) | (74.20) | (89.68) | 6.48 | (62.67) | (57.27) | (78.88) | (11.42) | (2.46) |
EPS (Diluted) |
(75.64) | (66.99) | (74.20) | (89.68) | 6.48 | (62.67) | (57.27) | (78.88) | (11.42) | (3.26) |
Shares (Basic, Weighted) |
0.76 | 0.87 | 1.00 | 1.18 | 1.32 | 1.41 | 1.49 | 1.50 | 2.57 | 7.42 |
Shares (Diluted, Weighted) |
0.76 | 0.87 | 1.00 | 1.18 | 1.33 | 1.41 | 1.49 | 1.50 | 2.57 | 7.78 |
Gross Margin |
100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 82.65% | 70.56% | 91.31% | — |
EBIT Margin |
(67,906.98%) | (6,529.64%) | (574.52%) | (561.60%) | 3.99% | (386.85%) | (209.08%) | (579.43%) | (393.82%) | — |
EBT margin |
(67,148.84%) | (6,402.74%) | (552.39%) | (539.02%) | 5.71% | (384.06%) | (204.16%) | (565.21%) | (411.90%) | — |
Net Profit Margin |
(66,604.65%) | (6,380.35%) | (549.51%) | (534.91%) | 6.23% | (384.06%) | (204.16%) | (565.21%) | (411.90%) | — |
Free Cash Flow Margin |
(55,927.91%) | (6,020.20%) | (166.11%) | (549.35%) | (4.32%) | (260.80%) | (188.15%) | (450.46%) | (271.14%) | — |
EBITDA |
(57.15) | (59.57) | (78.83) | (112.26) | 6.55 | (86.67) | (85.60) | (119.56) | (28.01) | (26.85) |
EBIT |
(58.40) | (59.48) | (77.38) | (111.68) | 5.39 | (89.08) | (87.53) | (121.49) | (28.11) | (26.75) |
Income from Continuous Operations |
(57.28) | (58.12) | (74.01) | (106.37) | 8.41 | (88.44) | (85.47) | (118.51) | (29.40) | (18.21) |
Consolidated Net Income/Loss |
(57.28) | (58.12) | (74.01) | (106.37) | 8.41 | (88.44) | (85.47) | (118.51) | (29.40) | (18.21) |
EPS (Basic, from Continuous Ops) |
(75.63) | (67.09) | (74.27) | (89.79) | 6.39 | (62.81) | (57.36) | (78.81) | (11.42) | (2.45) |
EPS (Basic, Consolidated) |
(75.63) | (67.09) | (74.27) | (89.79) | 6.39 | (62.81) | (57.36) | (78.81) | (11.42) | (2.45) |
EPS (Diluted, from Cont. Ops) |
(75.63) | (67.09) | (74.27) | (89.79) | 6.32 | (62.81) | (57.36) | (78.81) | (11.42) | (2.34) |
Shares (Diluted, Average) |
0.76 | 0.87 | 1.00 | 1.18 | 1.33 | 1.41 | 1.49 | 1.50 | 1.52 | 7.78 |
EPS (Diluted, Consolidated) |
(75.63) | (67.09) | (74.27) | (89.79) | 6.32 | (62.81) | (57.36) | (78.81) | (11.42) | (2.34) |
EBITDA Margin |
(66,456.98%) | (6,539.19%) | (585.28%) | (564.52%) | 4.85% | (376.36%) | (204.46%) | (570.21%) | (392.49%) | — |
Operating Cash Flow Margin |
(55,094.19%) | (6,018.33%) | (165.57%) | (549.26%) | (4.06%) | (260.93%) | (188.05%) | (439.14%) | (256.48%) | — |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 17, 2026